/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
CNS Pharmaceuticals, Inc. ( CNS, the Company, we, us, or our ) is a biotechnology company focused on developing innovative therapies for serious diseases in neurology and oncology. Together, these therapeutic areas represent hundreds of billions of dollars in annual global pharmaceutical spending, encompass some of the most prevalent and difficult to treat diseases affecting humanity, …
$5.11
$0.01 (-0.20%)
EOD Sep 18, 2026
Negative free cash flow of -$14M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$17M
▼ -6.7% YoY
Op. Margin
—
ROIC
-159.11%
▲ +123.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$13M
▲ +19.2% YoY
Op. Cash Flow (TTM)
-$13M
▲ +19.3% YoY
Net Debt
-$20M
Net Cash Position
Cash & Equiv.
$20M
Continue Research
SourceComputed from the 10-Q filed 12 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 13 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.